Small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases [Phase 2]
A Phase 2 trial evaluating radiotherapy combined with immunochemotherapy in pre-treated small cell lung cancer patients with liver metastase…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB) [Phase 2]
Phase 2 clinical trial update assessing tarlatamab (AMG 757) in metastatic/locally advanced small-cell lung cancer and other poorly differen…
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: This Study is an Open-lable, Phase I Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer. [Phase 1]
This is an open-label Phase I study evaluating the safety, feasibility, cytokinetics, and preliminary efficacy of GC511B in DLL3-positive re…
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)
Clinical trial update describing a study on long-term responders in metastatic lung cancer to improve management, currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers [Phase 1]
Phase 1 trial evaluating the radiopharmaceutical [212Pb]VMT-Alpha-NET across multiple somatostatin receptor–positive cancers, with recruitme…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC [EARLY_Phase 1]
An early-phase 1 clinical trial evaluating TC-D101, a DLL3-targeted CAR-T cell therapy, for DLL3-positive small cell lung cancer is currentl…
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer [Phase 1, Phase 2]
A dose-escalation Phase 1 study followed by expansion Phase 2 trial of ZG006 in advanced small cell lung cancer and neuroendocrine cancer, c…
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating YL201 in combination with Ivonescimab (AK112) for advanced solid tumors, including non-small cell lung…
-
CLINICAL_TRIALS research · 2025-11-12Clinical Trial Update: Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer [Phase 1]
This document announces a Phase 1 study of NMS-03305293 for adults with relapsed small cell lung cancer, currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) [Phase 1]
Phase 1 trial PRISM investigates personalized radiotherapy for extensive-stage small cell lung cancer with brain metastases; recruitment is …
-
CLINICAL_TRIALS research · 2025-10-31Clinical Trial Update: Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer [Phase 1]
A Phase 1 trial at Emory University is evaluating palliative radiotherapy in combination with lurbinectedin for extensive-stage small cell l…
-
CLINICAL_TRIALS research · 2025-10-29Clinical Trial Update: Biology of Young Lung Cancer Study: The YOUNG LUNG Study
The YOUNG LUNG Study is currently recruiting, focusing on the biology of lung cancer in younger patients.
-
CLINICAL_TRIALS research · 2025-10-28Clinical Trial Update: A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer [Phase 1]
Phase 1 study to evaluate how the investigational cancer drug BI 764532 is taken up by tumors in people with small cell lung cancer or neuro…
-
CLINICAL_TRIALS research · 2025-10-16Clinical Trial Update: Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients [Phase 1, Phase 2]
Clinical trial update describing a Phase 1/2 study of Quaratusugene ozeplasmid (Reqorsa) in combination with atezolizumab maintenance therap…
-
CLINICAL_TRIALS research · 2025-10-15Clinical Trial Update: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
An observational clinical trial from OncoHost Ltd. aims to predict responsiveness to anti-cancer treatments in patients with advanced cancer…
-
CLINICAL_TRIALS research · 2025-10-14Clinical Trial Update: Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies [Phase 1]
A Phase 1 study of JANX008 in advanced or metastatic solid tumors is currently recruiting, evaluating multiple indications including Non-Sma…
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: Penfluridol for Relapsed/Refractory Small Cell Cancers [Phase 1, Phase 2]
Phase 1/2 clinical trial update evaluating penfluridol for relapsed or refractory small cell cancers; the study is not yet recruiting.
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC). [Phase 2]
A Phase 2 trial investigates thoracic radiotherapy with maintenance durvalumab after first-line carboplatin and etoposide plus durvalumab in…
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung
A clinical trial registry entry describing a pragmatic analysis of complex radiotherapy cases in lung cancer (non-small cell and small cell)…
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer [NA]
Clinical trial update for NutriCare Plus, a medically tailored meal intervention, being studied in patients with various forms of lung cance…
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC [Phase 2]
Phase 2 clinical trial evaluating Adebrelimab in combination with chemoradiotherapy followed by Adebrelimab maintenance for limited-stage sm…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer [Phase 2]
A Phase 2 clinical trial evaluating BL-B01D1, SI-B003, and their combination in extensive-stage small cell lung cancer is currently recruiti…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit [Phase 1]
Phase 1 study evaluating NN3201, a c-Kit targeted antibody-drug conjugate, in advanced and/or metastatic solid tumors expressing c-Kit; curr…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC [Phase 2]
Phase 2 clinical trial evaluating AL8326 for safety and efficacy in second-line or later small cell lung cancer is currently active but not …
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) [Phase 1, Phase 2]
Phase 1/2 SKYBRIDGE study evaluating Peluntamig (PT217) in DLL3-expressing neuroendocrine carcinomas; currently recruiting.